Of the six patients with new-onset MPA, those who showed higher proportions of the T2ISG neutrophil subset exhibited persistent vasculitis symptoms. Elevated serum concentrations of interferon ...

is much broader than it was in the phase 3 clinical trial that led to its approval for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)–associated vasculitis (AAV), according to a ...

Nearly all (96%) patients with active AAV enrolled in the study achieved remission, with a median time to remission of 77 days. Early glucocorticoid withdrawal is feasible and was well tolerated ...

announced that NEFECON ® has been included in the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)" (hereinafter referred to as the "Guideline ...

Vaccines and ongoing vigilance are critical to prevent and manage infections in patients who are immunosuppressed or immunocompromised, according to a presenter at the Biologic Therapies Summit ...

Diagnosing systemic vasculitis remains a considerable clinical challenge, as does managing this disease after diagnosis. The general physician should have a working knowledge of vasculitis, including ...

VEXAS syndrome is known to be a mimicker of ANCA-associated vasculitis, making it a challenge to distinguish between the disorders. VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) ...

Credit: Getty Images With clinical trials investigating novel immunomodulatory approaches, the therapeutic landscape for treating vasculitis continues to evolve. Vasculitis refers to a group of ...